Pharmacokinetic approach to proglumide long-term activity.
In order to explain the long-term therapeutic activity of (+/-)-4-benzamide-N,-di-n-propylglutaramic acid (proglumide, Milid) a pharmacokinetic study was carried out in rats by three administration routes. As a result, experimental data could have been fitted to a tri- or tetra-exponential equation, with terminal half-life of about 24 h. Since human pharmacokinetics was found to be rather similar to that in rats, it can be extrapolated that steady state plasma level of drug during therapeutic dosage regimen should range around 60% of peak level of single administration.
D000818:Animals; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives*; D006207:Half-Life; D007700:Kinetics; D008954:Models, Biological; D011377:Proglumide / Q000378:metabolism* / Q000494:pharmacology; D051381:Rats; D013997:Time Factors
D005973:Glutamine; D011377:Proglumide